{"title":"[软件医疗器械的监管要求:欧洲、美国和阿尔及利亚的比较]。","authors":"Manel Belkhatir, Amina Mohammedi, Aida Ould Amar","doi":"10.1016/j.pharma.2025.06.001","DOIUrl":null,"url":null,"abstract":"<p><p>Software Medical Device (SWMD) are essential digital tools used in the healthcare sector for various medical applications. Like any medical device, MDS are subject to strict and rigorous regulations that vary from country to country, aiming to ensure their quality, safety, and effectiveness. This study examines the regulation of SWMD and compares the definitions, classifications, and approval processes in Algeria, Europe, and the United States, pointing out the similarities and differences among these regions. Regulatory documents were collected and analysed to provide an overview of the approaches adopted by each system. In Europe, Regulation (EU) 2017/745 (MDR) sets strict standards for the safety and effectiveness of medical devices, including software, with enhanced requirements for risk management, clinical evaluation, and post-market surveillance. In the United States, the FDA is the main regulatory body, with specific procedures for the classification, evaluation, and approval of devices. In Algeria, the regulatory framework for medical devices, including software, requires enhancement compared to these systems. This involves establishing regulatory requirements and guidelines that align with internationally recognized standards, such as ISO 13485, ISO 14971, and IEC 62304, which is specific to medical device software.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Regulatory requirements for software medical devices: Comparison between Europe, the United States, and Algeria].\",\"authors\":\"Manel Belkhatir, Amina Mohammedi, Aida Ould Amar\",\"doi\":\"10.1016/j.pharma.2025.06.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Software Medical Device (SWMD) are essential digital tools used in the healthcare sector for various medical applications. Like any medical device, MDS are subject to strict and rigorous regulations that vary from country to country, aiming to ensure their quality, safety, and effectiveness. This study examines the regulation of SWMD and compares the definitions, classifications, and approval processes in Algeria, Europe, and the United States, pointing out the similarities and differences among these regions. Regulatory documents were collected and analysed to provide an overview of the approaches adopted by each system. In Europe, Regulation (EU) 2017/745 (MDR) sets strict standards for the safety and effectiveness of medical devices, including software, with enhanced requirements for risk management, clinical evaluation, and post-market surveillance. In the United States, the FDA is the main regulatory body, with specific procedures for the classification, evaluation, and approval of devices. In Algeria, the regulatory framework for medical devices, including software, requires enhancement compared to these systems. This involves establishing regulatory requirements and guidelines that align with internationally recognized standards, such as ISO 13485, ISO 14971, and IEC 62304, which is specific to medical device software.</p>\",\"PeriodicalId\":8332,\"journal\":{\"name\":\"Annales pharmaceutiques francaises\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annales pharmaceutiques francaises\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.pharma.2025.06.001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales pharmaceutiques francaises","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.pharma.2025.06.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
[Regulatory requirements for software medical devices: Comparison between Europe, the United States, and Algeria].
Software Medical Device (SWMD) are essential digital tools used in the healthcare sector for various medical applications. Like any medical device, MDS are subject to strict and rigorous regulations that vary from country to country, aiming to ensure their quality, safety, and effectiveness. This study examines the regulation of SWMD and compares the definitions, classifications, and approval processes in Algeria, Europe, and the United States, pointing out the similarities and differences among these regions. Regulatory documents were collected and analysed to provide an overview of the approaches adopted by each system. In Europe, Regulation (EU) 2017/745 (MDR) sets strict standards for the safety and effectiveness of medical devices, including software, with enhanced requirements for risk management, clinical evaluation, and post-market surveillance. In the United States, the FDA is the main regulatory body, with specific procedures for the classification, evaluation, and approval of devices. In Algeria, the regulatory framework for medical devices, including software, requires enhancement compared to these systems. This involves establishing regulatory requirements and guidelines that align with internationally recognized standards, such as ISO 13485, ISO 14971, and IEC 62304, which is specific to medical device software.
期刊介绍:
This journal proposes a scientific information validated and indexed to be informed about the last research works in all the domains interesting the pharmacy. The original works, general reviews, the focusing, the brief notes, subjected by the best academics and the professionals, propose a synthetic approach of the last progress accomplished in the concerned sectors. The thematic Sessions and the – life of the Academy – resume the communications which, presented in front of the national Academy of pharmacy, are in the heart of the current events.